Dr. Richard Soll is joining Pepticom’s SAB

We are very excited to announce Dr. Soll joining Pepticom’s Scientific Advisory Board.
Presently Senior Advisor, Strategic Initiatives at WuXi AppTec and Head of the WuXi office in Boston, Massachusetts, Dr. Soll’s contributions have led to the discovery of the HCV NS5A inhibitor in the Merck-WuXi partnership, the JAK2 inhibitor Fedratinib at TargeGen (partnered with Celgene/BMS), and more than 10 other clinical stage drugs throughout his career.

Dr. Soll is also a board observer for Proniras and is an advisory board member with the Blavatnik Center for Drug Discovery at Tel Aviv University, the Children’s Tumor Foundation, and the Pistoia Alliance. Welcome!